180 Wealth Advisors LLC Grows Position in MannKind Co. (NASDAQ:MNKD)

180 Wealth Advisors LLC increased its stake in shares of MannKind Co. (NASDAQ:MNKD) by 1.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,105,707 shares of the biopharmaceutical company’s stock after buying an additional 21,170 shares during the quarter. MannKind makes up about 2.1% of 180 Wealth Advisors LLC’s portfolio, making the stock its 7th largest position. 180 Wealth Advisors LLC’s holdings in MannKind were worth $13,540,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Commonwealth Equity Services LLC boosted its position in MannKind by 6.0% during the second quarter. Commonwealth Equity Services LLC now owns 68,361 shares of the biopharmaceutical company’s stock worth $357,000 after purchasing an additional 3,861 shares during the period. Rhumbline Advisers lifted its holdings in shares of MannKind by 5.2% in the second quarter. Rhumbline Advisers now owns 397,194 shares of the biopharmaceutical company’s stock worth $2,073,000 after buying an additional 19,675 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of MannKind in the second quarter valued at approximately $1,524,000. Renaissance Technologies LLC purchased a new position in MannKind during the second quarter valued at approximately $67,000. Finally, AQR Capital Management LLC increased its holdings in MannKind by 8.1% during the 2nd quarter. AQR Capital Management LLC now owns 42,730 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 3,214 shares during the period. Hedge funds and other institutional investors own 49.55% of the company’s stock.

Insider Buying and Selling at MannKind

In other news, Director Steven B. Binder sold 67,536 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $6.89, for a total transaction of $465,323.04. Following the completion of the sale, the director now owns 1,075,026 shares of the company’s stock, valued at approximately $7,406,929.14. This represents a 5.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Stuart A. Tross sold 55,000 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $7.34, for a total transaction of $403,700.00. Following the sale, the insider now owns 967,191 shares of the company’s stock, valued at $7,099,181.94. This represents a 5.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 190,075 shares of company stock worth $1,325,587 over the last ninety days. Insiders own 3.00% of the company’s stock.

MannKind Trading Up 0.7 %

Shares of MannKind stock opened at $6.13 on Tuesday. The business’s 50-day moving average price is $6.70 and its 200-day moving average price is $6.22. The firm has a market capitalization of $1.69 billion, a PE ratio of 87.57 and a beta of 1.29. MannKind Co. has a 12 month low of $3.17 and a 12 month high of $7.63.

Analyst Ratings Changes

MNKD has been the subject of a number of recent analyst reports. Royal Bank of Canada raised shares of MannKind from a “sector perform” rating to an “outperform” rating and upped their price target for the stock from $7.00 to $10.00 in a report on Thursday, December 19th. StockNews.com lowered MannKind from a “buy” rating to a “hold” rating in a research note on Saturday, December 7th. Finally, Wells Fargo & Company started coverage on MannKind in a research report on Friday, December 20th. They set an “overweight” rating and a $9.00 price target for the company. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $9.07.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.